Metrics as of 10/14/2026, 05:38 PM (Berlin time), refresh in progress.
Nektar Therapeutics Stock
Nektar Therapeutics
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Howard W. Robin
- Employees
- 63
- Market cap
- $1.1 B
- IPO
- 03/05/1994
Nektar Therapeutics is a biopharmaceutical firm in the Healthcare sector, headquartered in San Francisco, USA. Established in 1990, the company is dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its pipeline is Bempegaldesleukin, a…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Nektar Therapeutics stock: price history
1D
-2.7%
1W
-8.4%
1M
-46.1%
6M
-55.7%
YTD
-12.7%
1Y
-35.4%
2Y
+86.3%
5Y
-85.8%
10Y
-84.5%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~100% stronger price swings than usual
Ask the agents about Nektar Therapeutics
Analyst assessment of Nektar Therapeutics
PRICE TARGET LOW
US$50.00
CONSENSUS
US$130.43
MEDIAN
US$150.00
PRICE TARGET HIGH
US$192.00
0
STRONG BUY
22
BUY
6
HOLD
5
SELL
0
STRONG SELL
33
TOTAL · Buy
As of: 09/10/2026
Nektar Therapeutics stock metrics
P/E
-5.51
P/B
1.35
EV/EBITDA
-8.61
RETURN ON EQUITY
-4.5%
NET MARGIN
-401.0%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
101.6%
FLOAT SHARES
29,141,804
AVG. DAILY VOLUME (30D)
1,663,424
Insider transactions (SEC)
CHESS ROBERT
WHITFIELD ROY A
GREER R SCOTT
Brainard Diana
Ajer Jeffrey Robert
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.7%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Nektar Therapeutics stock
What does Nektar Therapeutics do?
Nektar Therapeutics is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Howard W. Robin, the company employs around 63 people.
The IPO was on 03/05/1994; the stock trades on NASDAQ under the ticker NKTR.
What do analysts say about Nektar Therapeutics stock?
33 analysts rate the stock, the consensus is Buy (as of 09/10/2026).
The average price target is US$130.43, ranging from US$50.00 to US$192.00, with a median of US$150.00.
This is an external assessment, not a statement by Market Jury.
When does Nektar Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 100% stronger than usual.
Does Nektar Therapeutics pay a dividend?
No, Nektar Therapeutics currently does not pay a dividend.
Which stocks are comparable to Nektar Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Nektar Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Nektar Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.